Obiltoxaximab Injection [Anthim]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials are being…
Obiltoxaximab (Anthim®, ETI-204) is a monoclonal antibody that is being developed by Elusys Therapeutics and the US Department of…